Variables | N (%) or mean ± SD | Median with IQR |
---|---|---|
Female (N, %) | 66 (97.1%) | |
Age (years) | 31.7 ± 10.0 | 32 (23, 38) |
Body weight (kg) | 54.7 ± 14.9 | 50.9 (45.9, 62) |
Body mass index | 20.1 ± 3.9 | |
Duration of SLE (years) | 6.3 ± 6.3 | 4 (2, 8.5) |
Systolic blood pressure (mmHg) | 126.7 ± 24.3 | 128 (119, 138.5) |
Diastolic blood pressure (mmHg) | 79.4 ± 19.2 | 78.5 (70, 92) |
Systemic organ involvements (N, %) | ||
Arthritis | 14 (20.6%) | |
Cutaneous lupus | 14 (20.6%) | |
Hematologic involvement | 8 (11.8%) | |
Serositis | 4 (5.9%) | |
Neurological involvement | 1 (1.5%) | |
Baseline SLEDAI score | 10.8 ± 3.3 | 10 (8, 12) |
Baseline Renal SLEDAI score | 7.0 ± 2.9 | 8 (4, 8) |
ISN/RPS class (N, %) | ||
Class III | 5 (7.4%) | |
Class IV | 49 (72.1%) | |
Class III + V | 4 (5.9%) | |
Class IV + V | 10 (14.7%) | |
Renal activity index | 8.5 ± 2.9 | 8 (6, 11.5) |
Renal chronicity index | 1.9 ± 1.7 | 2 (0, 3) |
Immunosuppressive agents (N, %) | ||
Induction with high cyclophosphamide | 37 (62.7%) | |
Induction with mycophenolate | 22 (37.3%) | |
Mean dose of mycophenolate (mg/day) | 29.6 ± 17.1 | 30 (20, 35) |
Prednisolone | 67 (98.5%) | |
Hydroxychloroquine | 32 (47.1%) | |
Anti-hypertensive and lipid lowering agents (N, %) | ||
RAAS blockers | 51 (75%) | |
Calcium channel blockers | 10 (14.7%) | |
Diuretics | 28 (41.2%) | |
Statins | 43 (63.2%) | |
Laboratory data | ||
Positive ANA (%) | 67 (98.5%) | |
Positive anti-dsDNA (%) | 57 (83.8%) | |
Low complement component 3 (C3) (%) | 31 (60.8%) | |
Serum complement component C3 levels (g/L) | 1.2 ± 1.8 | 0.7 (0.4, 1.1) |
Hematocrit (%) | 26.5 ± 11.2 | 30 (13.7, 34.6) |
Serum albumin (g/dL) | 2.7 ± 0.9 | 3 (2, 3.2) |
Serum creatinine (mg/dL) | 0.9 ± 0.5 | 0.8 (0.7, 1.1) |
Estimated GFR (mL/min/1.73 m2) | 89.6 ± 33.7 | 89.4 (63.7, 116.8) |
UPCR (g/g creatinine) | 5.9 ± 4.8 | 4.8 (2.5, 6.9) |